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Outcomes in stem cell transplantation (SCT) are modeled using probability theory. How-
ever, the clinical course following SCT appears to demonstrate many characteristics of
dynamical systems, especially when outcomes are considered in the context of immune
reconstitution. Dynamical systems tend to evolve over time according to mathematically
determined rules. Characteristically, the future states of the system are predicated on the
states preceding them, and there is sensitivity to initial conditions. In SCT, the interaction
between donorT cells and the recipient may be considered as such a system in which, graft
source, conditioning, and early immunosuppression profoundly influence immune recon-
stitution over time. This eventually determines clinical outcomes, either the emergence of
tolerance or the development of graft versus host disease. In this paper, parallels between
SCT and dynamical systems are explored and a conceptual framework for developing
mathematical models to understand disparate transplant outcomes is proposed.
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Stem cell transplantation (SCT) represents a unique immunother-
apeutic modality in which donor-derived T cells exert a graft versus
host response, which when directed at host-derived malignancy,
effects a cure (1, 2). However, when this phenomenon extends to
normal host tissue, it results in the single most dreaded compli-
cation of this procedure, graft versus host disease (GVHD). Over
the years more stringent definition of human leukocyte antigen
(HLA) identity in donor–recipient pairs (DRP) has diminished the
likelihood of GVHD in HLA-matched pairs undergoing unrelated
donor SCT (3,4) such that in large patient populations it is seen less
frequently. But, take an individual patient – even one with a well-
matched sibling donor – and it is entirely impossible to predict
whether that individual will develop GVHD, requiring life-long
immunosuppression, or become a tolerant chimera, able to come
off immunosuppression (5, 6). Aside from the peri-transplant
pharmaco-therapeutic interventions, a number of biological fac-
tors impact the risk of developing GVHD (7). These include
mismatching of the minor histocompatibility antigens (mHA)
(8), the cytokine milieu (9, 10), and the “regulatory” immune
cell populations (11) in circulation at the time of transplantation.
So despite increasing stringency of HLA matching, a substantial
number of patients develop post-transplant complications, either
related to GVHD or to immunosuppression (infection, relapse),
contributing to therapeutic failure as evidenced by the frequent
observation of high-transplant related mortality following SCT (3,
12, 13). This suggests that outcomes following SCT are inherently
stochastic and subject to rules governing probability. So is there
some way individual outcomes may be determined following SCT,
in other words, is it possible to compute the fate of a transplant
recipient?
DO EARLY CONDITIONS AFFECT LATE OUTCOMES?
To ascertain this, a quantitative determination of the likelihood of
various post-transplant outcomes would have to be made in differ-
ent situations. As noted above, HLA matching represents a critical
variable in determining survival in transplant recipients. Exam-
ining the disparity in clinical outcomes of patients transplanted
using HLA matched and mismatched donors may give an indi-
cation of the quantitative effect of genetic variation at the major
histocompatibility (MHC) locus and the therapeutic adjustment
required to overcome that. Over the last decade, transplant out-
comes observed in patients undergoing alternative donor SCT have
steadily improved with relatively minor adjustments to transplant
technique. As an example, poor outcomes following umbilical cord
blood transplantation (UCBT) in adults were improved by infus-
ing two cord blood units, despite the HLA mismatch between the
recipients and the donor cords (14, 15). Graft loss likelihood as well
as infection rates declined and no increase in GVHD was observed,
even though in the long run only one of the cord blood units would
engraft. In a strictly quantitative sense, if not qualitative, the stem
cell dose was not significantly altered with the double cord blood
infusion when compared with the dose administered using an
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adult donor, where it was an order of magnitude higher. Similarly,
SCT from a haploidentical related donor had been consistently
fraught with poor outcomes until the institution of cyclophos-
phamide infusion on day 3 and 4 following transplant. This has
resulted in a marked improvement in survival following SCT with
haploidentical donors, even in the absence of T cell depletion (16,
17). In both these examples, interventions early in the transplant
course led to a lasting impact on the long-term outcome, with no
further intervention beyond the norm. This occurred despite lack
of HLA identity, and has led to these mismatched donor sources
now being considered viable alternatives if HLA-matched donors
are not available. Even when HLA-mismatched unrelated donors
are considered, although the transplant risk is higher compared to
an HLA-matched donor, with modern conditioning and GVHD
prophylaxis regimens, survival, and GVHD incidence is relatively
similar regardless of whether donors are mismatched at either the
allele or antigen level (18, 19). Further, in HLA-matched unrelated
donors early interventions such as infusion of anti-thymocyte
globulin (20, 21) or bortezomib (22) prior to stem cell infusion
have resulted in marked impact on long-term outcomes. As an
example, a small difference in the dose of ATG given during con-
ditioning may have long-term effects on the clinical endpoints
occurring much later in the course of transplant, presumably by
impacting immune reconstitution (23). These examples illustrate
the principle that, conditions early on in the course of transplan-
tation are critical in determining long-term outcome, to the extent
that they may compensate HLA mismatch. This sensitivity to early
conditions is a characteristic of deterministic systems, as opposed
to systems governed by randomness.
Further evidence of long-term effects of early conditions comes
from examination of immune reconstitution following HLA-
matched SCT. It has been a consistent observation that early
donor-derived lymphoid recovery is associated with improved
clinical outcomes (Figure 1); less graft loss and relapse,albeit, at the
expense of greater GVHD risk (24–29). Conversely, poor donor-
derived lymphoid recovery either in the form of mixed chimerism
or in the terms of low-absolute lymphocyte count (ALC) puts
patients at risk for eventual graft loss or relapse, particularly when
reduced intensity conditioning regimens are being used (30, 31).
ARE TRANSPLANT OUTCOMES DETERMINISTIC?
Within patients with normal immune recovery there remains an
inability to predict whether they will develop alloreactivity or not.
This has been explained by the presence of different mHA out-
side the MHC locus. Numerous studies have documented the
association of various specific mHA, or groups of mHA, with
alloreactivity. However, when whole exome sequences of the SCT
donors and recipients were compared, identifying all the single
nucleotide polymorphisms in a unique DRP, and thus, the poten-
tial mHA between them, an extensive library of thousands of
potential variant mHA was seen in HLA-matched pairs, making
it unlikely that GVHD occurrence can be explained on the basis
of histo-incompatibility alone (32). The large burden of minor
histo-incompatibility implies that the likelihood of alloreactiv-
ity manifesting clinically may be determined by the degree of
allo-antigen presentation at the time of transplant, which in turn
is determined by the degree of tissue injury and inflammation.
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FIGURE 1 | Early lymphoid recovery influences clinical outcomes
following allogeneic SCT. Absolute lymphocyte count (ALC) at 1 month
predicts survival. As 1-month ALC increased by 1/10, the odds of survival
increased by over 3% (HR=3.25; 95% CI: 1.59–6.62; P =0.001). Similarly,
as 1-month ALC increased by 1/10, the odds of relapse decreased by over
3% (HR=0.33; 95% CI: 0.16–0.66; P = 0.002) not shown. Adapted from
Ref. (24).
The immunosuppressive milieu at the time the initial interaction
between T cells and antigen presenting cells occurs then becomes a
critical factor in determining tolerance or alloreactivity emerging.
The principle at hand appears to be that, all donor–recipient pairs
will have immunogenic potential for alloreactivity, and in most
instances very early on in the course of SCT they will be propelled
on a path to certain clinical outcomes (tolerance versus GVHD
versus graft loss), in a deterministic fashion.
Further support for determinism comes from immune recov-
ery following SCT, which follows predictable kinetics in terms
of the order in which various immune cell subsets reconstitute.
Commonly, NK cell recovery is prompt, within a few weeks of
transplantation followed by cytotoxic T cell recovery, with B cells
and helper T cells lagging significantly, especially in patients under-
going T cell depletion. When T cell subsets emerging following
SCT are examined with respect to the T cell receptorβ (TRB) reper-
toire complexity, oligoclonal expansion has been observed, which
over time recovers back to a more normal repertoire. Importantly,
when studied using next generation sequencing (NGS), the T cell
repertoire is not disordered, rather, it has a fractal ordering with
respect to gene segment usage, which may be described mathe-
matically (33). Fractals describe the geometry of many objects in
nature, and are characterized by self-similarity over different scales
of measurement. In the human T cell repertoire, proportionality
in magnitude is maintained across scales of measurement, when T
cell clonal frequency is examined in terms of TRB, variable, diver-
sity, and joining gene segment usage. This suggests that a fractal
model may be appropriate to describe immune reconstitution fol-
lowing SCT, strengthening the argument for SCT outcomes being
deterministic. Given its immunoablative nature, SCT provides a
good opportunity to examine the recovery kinetics of T cells,which
appear to be influenced by the donor type and the conditions at
the time of cell infusion, i.e., use of T cell depletion, or immuno-
modulators. Thus, even though the rate of T cell reconstitution
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may vary in individuals, quantitatively it may be defined math-
ematically, and this implies the principle that T cell repertoire
reconstitution kinetics follows a deterministic course.
STEM CELL TRANSPLANTS AS DYNAMICAL SYSTEMS
Considering these principles, sensitivity to early conditions, which
in a complex background of antigenic diversity leads to different
outcomes, arrived at by computable immune response; one may
postulate that SCT when viewed in individual DRP is an exam-
ple of a dynamical system. In other words, when followed over
the course of time after transplantation, each future state of the
transplant DRP (system) is dependent upon the state immediately
preceding it, rather than being a random occurrence. Such dynam-
ical systems evolve over time, and their evolution is modeled by
differential equations. These systems may be precisely predictable,
as in an accelerating object, where depending on the physical char-
acteristics of the object, one would get the anticipated acceleration
every time energy is applied. On the other hand, outcomes in cer-
tain dynamical systems may be more difficult to precisely predict,
in other words chaotic, as in the case of weather, where a complex
system influenced by a large number of variables, demonstrates
disparate outcomes because its evolution over time is extremely
sensitive to initial conditions. Thus, even though the behavior of
chaotic systems is governed by mathematically described rules, as
the system goes through successive iterations over time, the even-
tual outcomes in different individuals diverge exponentially as a
function of time. This occurs because minor differences in initial
conditions get magnified with the passage of time as the system
evolves in each individual. The important concept to recognize
in these systems is that if the initial conditions can be faithfully
reproduced, chaotic systems will generally have similar outcomes
each time, however, even very small fluctuations in these condi-
tions sends the system down a different trajectory to an altogether
different outcome state in different individuals or instances. Fur-
ther, all the possible potential outcomes, or states, constitute the
phase space of that system, and generally individual systems tend
toward a limited number of states, mathematical entities termed
“attractors” (34–37).
Clearly, SCT does not follow our first dynamical system model,
since despite the most well designed conditioning regimens and
stringently selected donors, outcomes in individual patients are
highly variable. Laws of probability can give the odds of a certain
outcome, but cannot chart the course an individual will follow
after SCT. Further, between genomic variation between donor
and recipient, donor-derived T cell repertoire, recipient cytokine
milieu and microbiome as well as pathogen exposure, the num-
ber of variables to consider is much too great to expect linear,
predictable behavior. Therefore, in view of the above discussion,
dynamical system modeling of SCT is necessary to understand
disparate outcomes, particularly when sensitivity to early condi-
tions is borne in mind. To accomplish this differential equations
describing the kinetics of T cell clonal reconstitution over time
following SCT, and relating them to the eventual development
of either GVHD or tolerance (relapse) may be developed to
explore this idea. In such a model, the GVHD risk will depend
upon the cumulative effect of the proliferating T cell clones in a
deterministic fashion, rather than in a probabilistic manner.
So is it important to distinguish between stochastic or deter-
ministic outcomes following SCT? There is an important differ-
ence between the two models: in the former, GVHD or tolerance
or relapse, would develop randomly, without any underlying rule
or principle being followed. In dynamical systems, however, there
is an underlying set of rules that the system follows, and if the early
conditions can be precisely replicated, the outcomes in different
individuals will be more likely to be similar as the system evolves
(Table 1). Acknowledging the difficulty of replicating initial con-
ditions in SCT models precisely, knowledge of the rules at work in
SCT would nevertheless permit measured as opposed to empiric
therapeutic interventions, such as by more accurate titration and
timing of cellular and pharmacotherapy to achieve desired clinical
outcomes, within the limits of the system.
EVIDENCE FOR THE DYNAMICAL SYSTEMMODEL
What evidence exists that SCT represents a dynamical system? The
most telling evidence is the sensitivity to early conditions; consider
that in an HLA-matched SCT, minor histocompatibility antigens
(mHA) are a constant presence; these are there on the first day of
transplant, as they are one year later when the donor-derived T
cells are fully reconstituted. Yet, bortezomib or ATG or cyclophos-
phamide given during conditioning may result in the development
of tolerance in certain individuals, which in most instances does
not break even after withdrawal of immunosuppression. Regard-
less of the cellular mechanism of how this is achieved, the average
impact on the individual system in this instance is that the donor T
cells are propelled toward a specific outcome – tolerance – which in
this case would be analogous to an attractor, an endpoint to which
a chaotic dynamical system tends as it evolves over time. GVHD
on the other hand would represent an alternative attractor in the
system. An example of this is seen in lymphoid (T cell and NK
cell) recovery during the first 2 months following SCT, influenc-
ing eventual outcomes following SCT, whether they be survival,
relapse or GVHD (Figure 1) (14, 15, 38). The system “trajectory”
or output may be modified by an intervention; such as donor lym-
phocyte infusion (DLI) or intensification of immunosuppression
to treat GVHD, but left to itself it will tend toward one of the
“attractors.”
Additional support for a chaotic model of SCT comes from
the fractal organization of T cell repertoire. Chaotic systems may
be represented geometrically as fractals, which demonstrate iter-
ating patterns across scales of magnitude. T cell clonal frequency
when considered in terms of TRB, variable, joining, and diver-
sity gene segment usage has a fractal organization. This results
in a complex repertoire comprised of thousands of T cell clones,
which when examined in terms of clonal frequency, follow a Power
distribution, characteristic of self-similarity across scales of mea-
surement, at all levels of TRB clonal definition (33). Further, when
the genomic variability between donors and recipients is consid-
ered (32), and translated into putative mHA, the binding affinity
of the resulting peptides to the relevant HLA demonstrates a non-
linear, Power law distribution, reminiscent of the T cell clonal
distribution (Figure 2) (39). Therefore, one may postulate that
the driving force behind T cell reconstitution after SCT is the
spectrum of binding affinities of recipient mHA (and pathogen)
peptides with the relevant HLA in the individual transplant DRP,
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Table 1 | Characteristics of stochastic versus deterministic dynamical system modeling of SCT.
Stochastic Deterministic
Determining future outcomes
of SCT
Random; computed using probability function for specific
outcomes determined a priori
Dependent on early state of the system; computed
using iterating equations, such as the logistic equation
Source of variability in system
outcome
Unknown extrinsic or intrinsic factors; determined by
examining outcomes in large populations treated uniformly
Inherent property of growing system; mathematically
determined
Parameter needs for modeling
future states of the system
Limited Extensive
Computing probability of future
events
Average behavior of system in large populations Iterating, differential equations describing behavior of
system in individuals
Sensitivity to early conditions No Yes
Outcomes in individual with
identical early conditions
Variable Uniform
Clinical implications: GVHD
likelihood at time tn+1
Probability function of T cell reconstitution at earlier time tn Deterministic function of T cell reconstitution at earlier
time tn
Clinical implications:
post-transplant interventions
Timed according to probability of clinical outcome Timed according to measured parameters
Clinical implications: clinical trial
design
Uniform application of investigational therapy to population
to determine probability distribution of resulting outcomes
Individualized therapy based on parameter variation
(T cell reconstitution) and its association with desired
clinical outcome
Currently, SCT are modeled according to a limited number of known parameters such as, donor type, conditioning therapy, GVHD prophylaxis regimen, etc., in
such systems, outcomes in individual transplant recipients are stochastic. In a deterministic dynamical system model, parameters such as donor–recipient genomic
differences and their influence on the immune cell repertoire, and consequently on clinical outcomes are measured over time in individuals.This may allow prediction
of individual clinical outcomes.
encountered by donor T cells in the recipient. This is possibly the
case, as is evident in a comparison of the peptide-HLA binding
affinity distribution and T cell clonal frequency distribution from
two different studies performed by our group (Figures 2C,D). In
this model, depending on the initial conditions following SCT (T
cell dose infused+ cytokine milieu+ pharmacotherapy) specific
donor T cell clones will proliferate or decline in a deterministic
manner. The antigen presentation in the very beginning will result
in either alloreactive or pathogen specific T cell clones proliferat-
ing over time, and will eventually determine the clinical outcome,
either tolerance or GVHD (Figure 3).
MODELING T CELL CLONAL EXPANSION IN SCT
One model that may describe the cellular immune recovery fol-
lowing SCT is the logistic model of growth first described by
Verhulst in 1838 to explain population dynamics. Logistic growth
is described by an equation of the form:
xt+1 = r xt (1− xt ) .
In this equation, population size (N ) at discrete intervals of time
(t, t + 1, t + 2 . . .) is represented as a ratio, x, of the possible max-
imum population size at a much later time tn (carrying capacity,
K ). This ratio (x =N/K ), at any given time in the evolution of
a population (for example, xt+1) is always determined by the
population ratio from an earlier time (xt). In this iterating equa-
tion the term, r represents the maximum intrinsic growth rate
of the population and is called the “driving parameter” (36, 40).
This relationship has several implications; first, as the popula-
tion (in this case clonal frequency of individual T cell clones)
grows over time, its size at some final time will depend on both
the size of the starting population at t 0, and the value of r. Sec-
ond, after an initial period of exponential growth, the growth rate
slows down asymptotically because the term (1− xt) becomes
smaller as the population increases. Third, as the value of r
increases, the variance observed in x over time increases, eventu-
ally behaving in a chaotic manner. This is depicted in the Logistic
Map, where the values x takes on in the long-term, are plot-
ted against r (http://mathworld.wolfram.com/LogisticMap.html).
This demonstrates that while the value of x diminishes to zero over
time when r is<1, a steady increase in the value of x is observed as
r goes from 1 to 3; at r > 3 and <3.5, the system may take on two
different sets of values of x (bifurcation), consistent with a popu-
lation oscillating between two extremes; and finally, at r > 3.5 the
system behaves chaotically with large and unpredictable variation
in the value of x (and N ) over time. Despite this seemingly chaotic
behavior, however, if the logistic map is examined at ever-smaller
scales (higher decimal place values of r) the bifurcation patterns
of x seen in the larger map are reproduced in a self-similar manner
at each scale of magnification, revealing hidden structure in the
distribution of x with each increment in r, in other words, fractal
organization. If individual T cell clones are considered as unique
populations, this provides a plausible explanation for the fractal T
cell repertoire observed in SCT recipients.
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FIGURE 2 | (A) Model depicting the relationship between donor T cell
clonal frequency and recipient mHA-HLA binding affinity. (B) Postulated
association between peptide-HLA binding affinity and T cell clonal
frequency distribution. (C) T cell clonal frequency distribution1 and (D) the
values of reciprocal of IC502 (mHA-HLA binding affinity estimate) for
mHA-HLA in a single DRP. Both parameters follow a Power law
distribution, suggesting that peptide-HLA affinity spectrum has an
important role in determining T cell repertoire. Footnotes:1 T cell clonal
frequency measured on day 100 post SCT, by high throughput sequencing
of T cell receptor β, cDNA obtained from CD3+ cells, given in copy number
of unique clones and arranged in descending order with a cutoff at <100
copies. 21/IC50 of mHA-HLA complexes-(estimate of the binding affinity),
determined by whole exome sequencing to identify nsSNPs between
donor and recipient in the GVH direction, followed by in silico
determination of the resulting oligopeptide sequence, and the IC50 of the
resulting mHA-HLA complexes.
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FIGURE 3 | Modeling stem cell transplantation as a dynamical system.
Iterative expansion of donor T cells clones over time in the presence of an
alloreactivity potential, modulated by the degree of antigen presentation. In
(A) cells colored red, represent alloreactive T cell clones, and green cells,
other non-alloreactive T cell clones. Allo-antigen exposure or lack thereof in
the first few days of transplant results in minor early differences in the
repopulating T cell clones, which over time results in an exponential
expansion of corresponding T cell clones. Different phases of cellular
proliferation are labeled 1, 2, 3, and 4 in the schema and extrapolated to the
plots depicting absolute lymphocyte counts from two patients following SCT
(B). These plots show a bi-logistic growth pattern, reflecting initial
engraftment and cessation of mycophenolate mofetil following SCT.
Extrapolating this model to individual T cell clones followed
over time after SCT, one would observe very different growth
rates depending on the parameter r governing the growth of each
clone. And even though the proliferation of the T cell clones fol-
lows deterministic rules, chaotic behavior (if r is high enough)
means that, though the eventual clonal frequency of unique T cell
clones will be difficult to predict precisely, the overall repertoire
will demonstrate underlying order, as was observed in the fractal
ordering of the T cell repertoire. Further, the independence of x
from N in the logistic equation means that as the Logistic func-
tion iterates for each clone, relative proportionality is maintained
between T cell clonal populations as they vary over time, resulting
in the scale invariance characteristic of fractal geometry. In such
a model, the individual T cell clones may differ in their frequency
by orders of magnitude (41), however, this can be addressed by
employing a more complete and complex model of growth, such
as the Gompertz curve, which by taking Log x, accounts for the
logarithmic nature of growth in biological systems. A potential
additional advantage of this is that, it may describe sigmoid pop-
ulation growth more accurately than the Logistic growth curves
while also explaining chaotic growth behavior (42, 43).
This hypothesis is supported by the lymphocyte reconstitu-
tion kinetics observed in patients undergoing MRD and URD
SCT using an immunoablative reduced intensity conditioning
(Clinicaltrial.gov identifier: NCT00709592). In this regimen, thy-
moglobulin (either 5 or 7.5 mg/kg) was administered in divided
doses from day −9 to −7 followed by 4.5 Gray fractionated total
body irradiation. GVHD prophylaxis was with tacrolimus (day
−2 to approximately day 120) and mycophenolate mofetil (MMF;
day 0–30) (Figure 4A). In patients who achieved hematopoi-
etic engraftment, lymphocyte reconstitution could be plotted as
a function of time using a sigmoidal growth curve described by
the logistic equation. Most patients had two discernable peri-
ods of exponential increase in ALCs, one following engraftment
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FIGURE 4 | Absolute lymphocyte count (ALC, µL−1) plotted as a function of time (days following transplant). (A) Schema of the transplant protocol,
outlining the general immunosuppression withdrawal scheme. (B) ALC in the first month following SCT shows the first growth phase coincident with
engraftment.
(Continued )
(Figure 4B), and another period following cessation of MMF
(Figure 4C). These growth periods were followed by a plateau
with relatively stable lymphocyte counts in the absence of clini-
cal events, until withdrawal of tacrolimus when greater variability
was observed (Figure 4D). Patients developing complications of
therapy such as relapse, viral (CMV or EBV) reactivation, and
GVHD requiring immunosuppression, such as corticosteroid ther-
apy, had significant departures from the sigmoidal curve, as did
patients with delayed engraftment kinetics (Figure 4E). It should
be recognized that this data represents all the lymphocyte sub-
sets, such as NK, T, and B cells. The initial phase is likely largely
derived from NK cell recovery while the secondary phase most
www.frontiersin.org December 2014 | Volume 5 | Article 613 | 7
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FIGURE 4 | (C) ALC in the second and third month following SCT shows the second exponential growth phase following cessation of MMF, of these patients
only patient D developed GVHD.
(Continued )
likely represents T cell reconstitution. The latter postulate is con-
sistent with the finding that the day 60 donor-derived CD3+ cell
count is predictive of clinical outcomes (25). It is logical that total
lymphocyte counts would reflect the kinetics of T cell clonal pro-
liferation, and that this should be governed by the same principle
that describes population dynamics in general, i.e., it is a logistic
function of time. Therefore, lymphocyte count growth rate (r)
observed in our cohort may represent an average of the growth
rate of thousands of T cell clones following SCT. Thus, a simple
logistic growth model of T cell reconstitution may be developed
which would explain GVHD occurrence as an exponential increase
in alloreactive T cells, when immune reconstitution is considered
as an iterative process over time (Figure 3).
In SCT, r for each T cell clone may depend upon multiple
variables, including the antigen-HLA specificity of the T cell recep-
tor (Figure 2A), the immunosuppressive regimen being used and
the cytokine milieu during the period of growth as well as the
proportion of regulatory T cell clones. Further, it may vary as
immunosuppression is withdrawn following SCT (Figure 4A) or
inflammatory states, such as CMV reactivation or GVHD develop
leading to increasingly chaotic behavior of the T cell clones. On
the other hand, rate of change of x will depend not only on the
infused T cells, but will vary as hematopoietic precursors engraft
and depending on thymic integrity differentiate into immune cell
populations. It is important to recognize that in this dynamical
immune reconstitution model the chaotic behavior is occurring at
the level of the individual T cell clones, and while individual clones
may demonstrate marked variance in their frequency over time
following transplant, it is their cumulative effect, which, results in
GVHD or tolerance. If a large number of mHA directed T cell
clones proliferate, then the consequence would be GVHD. Con-
versely, if non-mHA directed T cell clones dominate, tolerance
ensues with immune reconstitution (Figure 3). In such a hypo-
thetical system, the total T cell count trends reflect the average
effects of this phenomenon, and the clinical outcomes are an effect
of this chaotic expansion of individual T cell clones, with GVHD
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FIGURE 4 | (D) ALC in the first 4–6 month following SCT shows the
overall growth kinetics of lymphocytes. Data in all these plots may be
modeled with a logistic equation of the general form, Nt =K/(1+Ae− rt),
where A= (K−N0)/N0, where N0 represents the lymphocyte count at
the beginning, and Nt is the lymphocyte count at time t following
transplant, e is the base of natural logarithms, 2.718 and r is the growth
rate of the population. A similar equation, Nt =N0 + (K−N0)/(1+10(a−t)r),
where a, is the time at which growth rate is maximal and an inflection
point is observed in the logistic curve, also describes the data.
(Continued )
and tolerance serving as the attractors. It may be postulated that
the restoration of a more “complete” fractal structure will result
in optimal clinical outcome. Studies demonstrating oligoclonal T
cell expansion in patients with GVHD or relapse demonstrate the
validity of this hypothesis (44–47). This concept is testable by mea-
suring the fractal dimension of the post-transplant T cell repertoire
by high-throughput sequencing (39). Therefore, if one can account
for the complexity at hand in SCT, perhaps by using NGS to study
the antigenic variance between donors and recipients, as well as T
cell clonotypes following SCT, it will likely be well described as a
chaotic dynamical system. Serial high-throughput sequencing of
TRB may allow plotting of the T cell clonal frequency as it evolves
over time following SCT, resulting in a plot which would yield
a fractal surface expanding over time, as individual T cell clones
vary and new clones emerge. Such analyses will likely be valuable
in distinguishing different prognostic groups of patients on the
basis of post-transplant T cell repertoire reconstitution.
Using the dynamical system model, one might monitor the
rate of change, in other words r, for the dominant T cell clones
following SCT and correlate this with clinical manifestations to
determine if this is associated with outcomes. Accurate mathe-
matical modeling of the dynamical evolution of T cell repertoire
following SCT would allow for measured, and earlier therapeutic
intervention in the event of either GVHD or inadequate immune
recovery or residual disease. For example, this may be an interven-
tion using more intense or prolonged post-transplant immuno-
suppression, for patients with rapid rate of change of x or those
with a high value of r, to reduce the risk of GVHD by reducing
the chaotic behavior if a large number of T cell clones have a
high r. Conversely, DLI may be similarly used when the opposite
conditions prevail. Further, knowledge of the critical time periods
when exponential T cell clonal growth occurs with different trans-
plant regimens will allow optimal timing of interventions such as
vaccination. For instance, vaccination may be best given before
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FIGURE 4 | (E) Patients with clinical events, depicting impact of immunosuppressive therapy on lymphocyte counts, and departure from the sigmoid growth
patterns. Also, seen is the variability from measurement to measurement in ALC in the fourth month, when comparing patients with GVHD (AA and D) and
those without (CC and DD).
the exponential rise in T cell numbers begins in order to maxi-
mize utilization of cytokines, and minimize potential competition
between T cell clones. This concept is utilized in lympho-depleting
chemotherapy regimens used as a part of adoptive immunother-
apy (48). Therefore, considering SCT as a dynamical system rather
than a stochastic one, would allow logic based patient management
and quantitative trial designs minimizing empiric interventions.
As such, therapy may be designed for individual patients based
on a systematic and personalized approach, instead of relying
on population-based outcomes derived from probabilistic study
designs. In essence, the development of accurate mathematical
models that account for the key variables influencing transplant
outcomes has the potential to improve clinical outcomes following
SCT, making SCT an even better example of personalized medicine
than it already is.
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